Clinical Trials Logo
  1. Home
  2. Myelodysplastic Syndromes (MDS)
  3. NCT06465953

Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation — PyramIDH  

Myelodysplastic Syndromes (MDS) Clinical Trial

Official title:
A Phase 3, Multicenter, Open Label, Randomized, Non-comparative Two-arm Study of Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Adult Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an Isocitrate Dehydrogenase-1 (IDH1) Mutation (PyramIDH Study)

Clinical Trial Summary

This study will enroll participants with myelodysplastic syndromes (MDS) with an Isocitrate dehydrogenase protein, 1 (IDH1) mutation, who have not received treatment with a hypomethylating agent previously. Participants will be randomized to receive either ivosidenib (IVO) alone or azacitidine (AZA) alone. IVO will be administered daily throughout the 28-day treatment cycle and AZA will be administered for the first 7 days of each 28-day cycle. Study visits will be conducted every week during Cycle 1 (Days 1, 8, 15, and 22), and Day 1 of each cycle thereafter. After the last dose of treatment, participants will attend an safety follow-up visit and participants will be followed to assess overall survival. Study visits may include a bone marrow aspirate, physical exam, echocardiogram (ECHO), electrocardiogram (ECG), blood and urine analysis, and questionnaires.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06465953
Study type Interventional
Source Servier
Contact Institut de Recherches Internationales Servier (I.R.I.S.), Clini
Phone +33 1 55 72 60 00
Email scientificinformation@servier.com
Status Not yet recruiting
Phase Phase 3
Start date December 30, 2024
Completion date December 1, 2028
View Details
See also
  Status Clinical Trial Phase
Completed NCT02550535 - A Phase I/II Study of Gene-modified WT1 TCR Therapy in MDS & AML Patients Phase 1/Phase 2
Completed NCT00186342 - Sibling and Unrelated Donor Hematopoietic Cell Transplant in Hematologic Malignancies N/A
Completed NCT00528983 - Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia Phase 1
Completed NCT01355913 - Screening and Genetic Monitoring of Patients With Myelodysplastic Syndromes (MDS) Under Different Treatment Modalities by Cytogenetic Analyses of Circulating CD34+Cells
Withdrawn NCT04985656 - A Study of Pevonedistat Combined With Decitabine and Cedazuridine in Adults With Higher-risk Myelodysplastic Syndromes Phase 2
Completed NCT01736683 - Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML) Phase 2
Completed NCT02333058 - Treosulfan-based Conditioning in Paediatric Patients With Haematological Malignancies Phase 2
Completed NCT01135849 - B-Receptor Signaling in Cardiomyopathy N/A
Withdrawn NCT04395092 - Haplo-identical Natural Killer (NK) Cells to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM) Phase 2
Completed NCT01885897 - IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT Phase 1/Phase 2
Recruiting NCT05092451 - Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances Phase 1/Phase 2
Recruiting NCT05884333 - Cord Blood Transplant in Adults With Blood Cancers Phase 2
Completed NCT02390414 - The Myelodysplasia Transplantation-Associated Outcomes (MDS-TAO) Study
Completed NCT01326377 - ON 01910.Na for Intermediate1-2, or High Risk Trisomy 8 Myelodysplastic Syndrome (MDS) Phase 2
Completed NCT02966782 - A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Participants With Relapsed/Refractory Myelodysplastic Syndromes (MDS) Phase 1
Recruiting NCT02779569 - A Clinical Trial Evaluating the Efficacy of Ultra Low Dose of Decitabine in Myelodysplastic Syndromes (MDS) N/A
Recruiting NCT02099669 - Red Blood Cell Transfusion Thresholds and QOL in MDS N/A
Completed NCT01392989 - Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders Phase 2
Not yet recruiting NCT06398457 - Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies Early Phase 1
Recruiting NCT02775383 - The National Myelodysplastic Syndromes (MDS) Study